The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Neuroprotective Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions.
The global Neuroprotective Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Neuroprotective Drugs in various end use industries. The expanding demands from the Alzheimer's disease, Parkinson's disease and Others,, are propelling Neuroprotective Drugs market. Cholinesterase inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-inflammatory segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neuroprotective Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neuroprotective Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neuroprotective Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neuroprotective Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neuroprotective Drugs covered in this report include Genervon, NeuroVive Pharmaceutical, Ceregene, BHR Pharma, Neuren Pharmaceuticals, Allon therapeutics and Bionure, etc.
The global Neuroprotective Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Genervon
NeuroVive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon therapeutics
Bionure
Global Neuroprotective Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neuroprotective Drugs market, Segment by Type:
Cholinesterase inhibitors
Anti-inflammatory
Others
Global Neuroprotective Drugs market, by Application
Alzheimer's disease
Parkinson's disease
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions.
The global Neuroprotective Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Neuroprotective Drugs in various end use industries. The expanding demands from the Alzheimer's disease, Parkinson's disease and Others,, are propelling Neuroprotective Drugs market. Cholinesterase inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-inflammatory segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neuroprotective Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neuroprotective Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neuroprotective Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neuroprotective Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neuroprotective Drugs covered in this report include Genervon, NeuroVive Pharmaceutical, Ceregene, BHR Pharma, Neuren Pharmaceuticals, Allon therapeutics and Bionure, etc.
The global Neuroprotective Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Genervon
NeuroVive Pharmaceutical
Ceregene
BHR Pharma
Neuren Pharmaceuticals
Allon therapeutics
Bionure
Global Neuroprotective Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neuroprotective Drugs market, Segment by Type:
Cholinesterase inhibitors
Anti-inflammatory
Others
Global Neuroprotective Drugs market, by Application
Alzheimer's disease
Parkinson's disease
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Neuroprotective Drugs Market Overview
1.1 Neuroprotective Drugs Product Overview
1.2 Neuroprotective Drugs Market Segment by Type
1.2.1 Cholinesterase inhibitors
1.2.2 Anti-inflammatory
1.2.3 Others
1.3 Global Neuroprotective Drugs Market Size by Type
1.3.1 Global Neuroprotective Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Neuroprotective Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Neuroprotective Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Neuroprotective Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Neuroprotective Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Neuroprotective Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Neuroprotective Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Neuroprotective Drugs Sales Breakdown by Type (2018-2023)
2 Global Neuroprotective Drugs Market Competition by Company
2.1 Global Top Players by Neuroprotective Drugs Sales (2018-2023)
2.2 Global Top Players by Neuroprotective Drugs Revenue (2018-2023)
2.3 Global Top Players by Neuroprotective Drugs Price (2018-2023)
2.4 Global Top Manufacturers Neuroprotective Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Neuroprotective Drugs Market Competitive Situation and Trends
2.5.1 Neuroprotective Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Neuroprotective Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuroprotective Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Neuroprotective Drugs Market
2.8 Key Manufacturers Neuroprotective Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Neuroprotective Drugs Status and Outlook by Region
3.1 Global Neuroprotective Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Neuroprotective Drugs Historic Market Size by Region
3.2.1 Global Neuroprotective Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Neuroprotective Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Neuroprotective Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Neuroprotective Drugs Forecasted Market Size by Region
3.3.1 Global Neuroprotective Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Neuroprotective Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Neuroprotective Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Neuroprotective Drugs by Application
4.1 Neuroprotective Drugs Market Segment by Application
4.1.1 Alzheimer's disease
4.1.2 Parkinson's disease
4.1.3 Others
4.2 Global Neuroprotective Drugs Market Size by Application
4.2.1 Global Neuroprotective Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Neuroprotective Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Neuroprotective Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Neuroprotective Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Neuroprotective Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Neuroprotective Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Neuroprotective Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Neuroprotective Drugs Sales Breakdown by Application (2018-2023)
5 North America Neuroprotective Drugs by Country
5.1 North America Neuroprotective Drugs Historic Market Size by Country
5.1.1 North America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Neuroprotective Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Neuroprotective Drugs Sales in Value by Country (2018-2023)
5.2 North America Neuroprotective Drugs Forecasted Market Size by Country
5.2.1 North America Neuroprotective Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Neuroprotective Drugs Sales in Value by Country (2024-2029)
6 Europe Neuroprotective Drugs by Country
6.1 Europe Neuroprotective Drugs Historic Market Size by Country
6.1.1 Europe Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Neuroprotective Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Neuroprotective Drugs Sales in Value by Country (2018-2023)
6.2 Europe Neuroprotective Drugs Forecasted Market Size by Country
6.2.1 Europe Neuroprotective Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Neuroprotective Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Neuroprotective Drugs by Region
7.1 Asia-Pacific Neuroprotective Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Neuroprotective Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Neuroprotective Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Neuroprotective Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Neuroprotective Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Neuroprotective Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Neuroprotective Drugs Sales in Value by Region (2024-2029)
8 Latin America Neuroprotective Drugs by Country
8.1 Latin America Neuroprotective Drugs Historic Market Size by Country
8.1.1 Latin America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Neuroprotective Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Neuroprotective Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Neuroprotective Drugs Forecasted Market Size by Country
8.2.1 Latin America Neuroprotective Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Neuroprotective Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Neuroprotective Drugs by Country
9.1 Middle East and Africa Neuroprotective Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Neuroprotective Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Neuroprotective Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Neuroprotective Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Neuroprotective Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Neuroprotective Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Genervon
10.1.1 Genervon Company Information
10.1.2 Genervon Introduction and Business Overview
10.1.3 Genervon Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Genervon Neuroprotective Drugs Products Offered
10.1.5 Genervon Recent Development
10.2 NeuroVive Pharmaceutical
10.2.1 NeuroVive Pharmaceutical Company Information
10.2.2 NeuroVive Pharmaceutical Introduction and Business Overview
10.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 NeuroVive Pharmaceutical Neuroprotective Drugs Products Offered
10.2.5 NeuroVive Pharmaceutical Recent Development
10.3 Ceregene
10.3.1 Ceregene Company Information
10.3.2 Ceregene Introduction and Business Overview
10.3.3 Ceregene Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Ceregene Neuroprotective Drugs Products Offered
10.3.5 Ceregene Recent Development
10.4 BHR Pharma
10.4.1 BHR Pharma Company Information
10.4.2 BHR Pharma Introduction and Business Overview
10.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 BHR Pharma Neuroprotective Drugs Products Offered
10.4.5 BHR Pharma Recent Development
10.5 Neuren Pharmaceuticals
10.5.1 Neuren Pharmaceuticals Company Information
10.5.2 Neuren Pharmaceuticals Introduction and Business Overview
10.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Neuren Pharmaceuticals Neuroprotective Drugs Products Offered
10.5.5 Neuren Pharmaceuticals Recent Development
10.6 Allon therapeutics
10.6.1 Allon therapeutics Company Information
10.6.2 Allon therapeutics Introduction and Business Overview
10.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Allon therapeutics Neuroprotective Drugs Products Offered
10.6.5 Allon therapeutics Recent Development
10.7 Bionure
10.7.1 Bionure Company Information
10.7.2 Bionure Introduction and Business Overview
10.7.3 Bionure Neuroprotective Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Bionure Neuroprotective Drugs Products Offered
10.7.5 Bionure Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Neuroprotective Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Neuroprotective Drugs Industrial Chain Analysis
11.4 Neuroprotective Drugs Market Dynamics
11.4.1 Neuroprotective Drugs Industry Trends
11.4.2 Neuroprotective Drugs Market Drivers
11.4.3 Neuroprotective Drugs Market Challenges
11.4.4 Neuroprotective Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Neuroprotective Drugs Distributors
12.3 Neuroprotective Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
